Loading
A phase 2 trial of Aminolevulinic acid (topical, for photodynamic therapy) in glioma & glioblastoma, run by Alpheus Medical, Inc., now recruiting.
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma is a phase 2 interventional study registered as NCT07225621 by Alpheus Medical, Inc., with 103 participants planned, started 2026-01-28 and due to reach its primary completion in 2027-12. Interventions recorded: 5-ALA HCl + LIDU SDT and Placebo + Sham SDT.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aminolevulinic acid (topical, for photodynamic therapy), Thermal ablation and cryotherapy for cervical precancer, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Aminolevulinic acid (topical, for photodynamic therapy) and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/